Skip to content

Research at St Andrews

A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma

Research output: Contribution to journalArticle

Author(s)

Gabriela Gremel, Dijana Djureinovic, Marjut Niinivirta, Alexander Laird, Oscar Ljungqvist, Henrik Johannesson, Julia Bergman, Perk-Henrik Edqvist, Sanjay Navani, Naila Khan, Tushar Patil, Åsa Sivertsson, Mathias Uhlén, David James Harrison, Gustav J. Ullenhag, Grant D. Stewart, Fredrik Pontén

School/Research organisations

Abstract

Background
There is an unmet clinical need for better prognostic and diagnostic tools for renal cell carcinoma (RCC).
Methods
Human Protein Atlas data resources, including the transcriptomes and proteomes of normal and malignant human tissues, were searched for RCC-specific proteins and cubilin (CUBN) identified as a candidate. Patient tissue representing various cancer types was constructed into a tissue microarray (n = 940) and immunohistochemistry used to investigate the specificity of CUBN expression in RCC as compared to other cancers. Two independent RCC cohorts (n = 181; n = 114) were analyzed to further establish the sensitivity of CUBN as RCC-specific marker and to explore if the fraction of RCCs lacking CUBN expression could predict differences in patient survival.
Results
CUBN was identified as highly RCC-specific protein with 58% of all primary RCCs staining positive for CUBN using immunohistochemistry. In venous tumor thrombi and metastatic lesions, the frequency of CUBN expression was increasingly lost. Clear cell RCC (ccRCC) patients with CUBN positive tumors had a significantly better prognosis compared to patients with CUBN negative tumors, independent of T-stage, Fuhrman grade and nodal status (HR 0.382, CI 0.203–0.719, P = 0.003).
Conclusions
CUBN expression is highly specific to RCC and loss of the protein is significantly and independently associated with poor prognosis. CUBN expression in ccRCC provides a promising positive prognostic indicator for patients with ccRCC. The high specificity of CUBN expression in RCC also suggests a role as a new diagnostic marker in clinical cancer differential diagnostics to confirm or rule out RCC.
Close

Details

Original languageEnglish
Article number9
Number of pages9
JournalBMC Cancer
Volume17
DOIs
Publication statusPublished - 4 Jan 2017

    Research areas

  • Cubilin, Renal cell carcinoma, Independent prognostic biomarker, Immunohistochemistry

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. The landscape of genomic copy number alterations in colorectal cancer and their consequences on gene expression levels and disease outcome

    Ried, T., Meijer, G. A., Harrison, D. J., Grech, G., Franch-Expósito, S., Briffa, R., Carvalho, B. & Camps, J., Oct 2019, In : Molecular Aspects of Medicine. 69, p. 48-61 14 p.

    Research output: Contribution to journalArticle

  2. Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031

    Sarr, A., Bré, J., Um, I. H., Chan, T. H., Mullen, P., Harrison, D. J. & Reynolds, P. A., 21 May 2019, In : Scientific Reports. 9, 13 p., 7643.

    Research output: Contribution to journalArticle

  3. Raman spectroscopy investigation of biochemical changes in tumor spheroids with aging and after treatment with staurosporine

    Jamieson, L. E., Harrison, D. J. & Campbell, C. J., May 2019, In : Journal of Biophotonics. 12, 5, e201800201.

    Research output: Contribution to journalArticle

Related by journal

  1. Fear of cancer recurrence trajectory during radiation treatment and follow-up into survivorship of patients with breast cancer

    Yang, Y., Cameron, J., Bedi, C. & Humphris, G., 20 Oct 2018, In : BMC Cancer. 18, 9 p., 1002.

    Research output: Contribution to journalArticle

  2. Improving quality of life through the routine use of the patient concerns inventory for head and neck cancer patients: a cluster preference randomized controlled trial

    Rogers, S. N., Lowe, D., Lowies, C., Yeo, S. T., Allmark, C., Mcavery, D., Humphris, G. M., Flavel, R., Semple, C., Thomas, S. J. & Kanatas, A., 18 Apr 2018, In : BMC Cancer. 18, 10 p., 444.

    Research output: Contribution to journalArticle

  3. Serum and blood based biomarkers for lung cancer screening: a systematic review

    Chu, G. C. W., Lazare, K. & Sullivan, F., 13 Feb 2018, In : BMC Cancer. 18, 6 p., 181.

    Research output: Contribution to journalReview article

ID: 248482316

Top